reason report
innov growth highlight analyst day pt
bottom line recent attend iqv analyst day new
york come away encourag continu innov
compani pursu increas revenu growth anticip
goal unveil analyst day
encourag good view support posit outlook
introduc recent initi late may link mid-
term guidanc increas rel prior guidanc re-
affirm outlook like continu evolv
improv offer aim creat orchestr clinic
trial platform encourag larg identifi
manag plan creat virtual trial also innov
view think reduc cost clinic trial improv
effici speed well encourag appear
well posit support shift value-bas pharmaceut
payment arrang view remain innov compani
strong grow market present signific long-term
opportun continu revenu earn growth maintain
outperform rate increas price target
mid-term guidanc increas increas mid-term guidanc
analyst day guid robust revenu compound-annual-growth-rate
 bolster
 significantli prior guid growth
similarli adj ebitda growth guidanc rais expect
rang lead continu double-digit adj
ep growth notabl anticip de-lever
manag explain larg function
anticip adj ebitda growth total revenu guid
compound-annual-growth-rate expect driven primarili
analyt solut ta ds segment
expect achiev revenu cagr
respect guidanc re-affirm
new oper excel program deliv addit
annual save addit mid-term guidanc provid
analyst day announc new oper excel program
aim deliv annual run rate save end
addit annual run rate save
compani alreadi extract follow merger
net debt total capit
price-to-earnings lt ep growth
ep
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm
ep exclud stock comp restructur transact one-tim item
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
guidanc re-affirmed encourag re-affirm
guidanc analyst day total revenu still expect
rang bracket prior svb leerink/
consensu revenu estim adj ep guidanc
align era orchestr analyst day
manag explain believ next big thing clinic
trial orchestr variou capabl current
mani point solut clinic trial yet
one unifi platform work seamlessli across continuum
clinic trial way work connect variou platform
creat one streamlin intellig workflow one ecosystem
tie togeth clinic data real world evid cloud platform
orchestr interact trial design start-up contact
close addit help client orchestr
ad benefit creat larg address market across
four domain clinic real world complianc commerci
manag explain see larg market opportun
find encourag
re-imagin clinic trial model virtual trial
plan re-imagin clinic trial model attempt creat
virtual trial would disrupt tradit site-bas clinic trial
model accord manag individu live two
hour given clinic research facil make recruit
particip difficult de-centr clinic trial
creat virtual trial imagin could streamlin process
speed time take start trial reduc time take
recruit patient make entir trial process easier
patient physician encourag pursu
relationship salesforc make virtual trail realiti
encourag leverag new technolog pursu continu
evolut model
well posit novel payment arrang among
variou pressur impact life scienc industri highlight
payer consolid rise specialti pharmaceut product
increasingli pressur tradit commerci agreement
drug product leverag vast data set includ
de-identifi patient record one million data feed
collect healthcar record annual explain
well posit help facilit adopt new novel payment
arrang tie payment pharmaceut product variou
outcom condit believ shift valu continu
increas preval import high-cost specialti
pharmaceut product like necessit use new payment
mechan tie spend result
tweak estim price target follow analyst
day tweak model reflect mid-term guid
manag comment increas adj ep
nickel modestli increas revenu
estim rais price target slightli
higher multipl believ warrant given better
expect mid-term growth target introduc analyst day
iqvia previous known quintilesim form follow merger
quintil im health iqvia offer cover broad section healthcar
landscap primari focu life scienc servic technolog well clinic
research one largest contract research organ cro world iqvia
forefront technolog innov drug develop healthcar industri
offer rang across research develop applic real world analyt
outcom commerci technolog iqvia captur signific portion
market drive toward digit healthcar iqvia improv
overal effici system also creat vast databas de-identifi data
use continu drive industri forward data improv analyt
iqvia work maxim effici clinic trial smart process inform
drive better quicker result allow product enter system way benefit
manufactur well patient larg cro extens technolog data
analyt capabl believ combin solut quintil im creat highli
attract platform manufactur embrac leader industri expect
iqvia continu drive innov improv outcom util data
asset technolog innov rate share outperform
takeaway iqv analyst day
recent attend iqv analyst day new york overal come away
event encourag progress made follow merger continu
innov compani pursu target unveil analyst day
encourag good view support posit outlook introduc recent
initi late may link mid-term guidanc increas rel prior
guidanc re-affirmed guidanc also encourag analyst
day learn sever opportun growth includ orchestr
clinic trial virtual trial abil support promot new commerci agreement
life scienc custom view remain innov compani strong grow
market present signific opportun continu revenu earn growth
maintain outperform rate increas forward revenu earn
innov engin drive increas mid-term guid
encourag increas mid-term guidanc book-end analyst day
discuss new target meaning ahead prior mid-term guidanc
manag expect total compani revenu grow compound-annual-growth-rate bolster
bp impli robust mid-to-high singl digit organ growth new guid
substanti prior mid-term guid growth similarli adj ebitda growth
rais expect grow rang lead continu double-
digit adj ep growth notabl anticip de-lever
manag explain larg function anticip adj ebitda growth
 manag explain anticip take addit debt expect adj
ebitda growth natur lead de-lever
figur increas target encourag fuel continu growth
total revenu guid compound-annual-growth-rate expect driven primarili
analyt solut ta ds segment
expect achiev revenu cagr respect cfo michael
mcdonnel explain ta segment bp growth expect come
 ds segment growth expect impact bp headwind
pass-through revenu expect off-set bp contract sale
manufactur servic csm divis reportedli stabil expect
gener revenu growth mainli driven reorgan go-to-market strategi
oper excel program target addit save year-end
addit mid-term guidanc provid analyst day announc new
oper excel program aim deliv annual run rate save
end addit annual run rate save compani
alreadi extract follow merger
figur new oper excel program target addit save
overal believ mid-term guidanc encourag like continu
drive innov continu growth margin expans new mid-term revenu
guid ahead prior estim call revenu growth
like continu innov
win share also remain vigil cost save opportun
also encourag re-affirm guidanc analyst day total
revenu still expect rang bracket prior svb
leerink/consensu revenu estim adj ep guidanc
similarli bracket prior svb leerink/consensu estim overal
encourag reaffirm guid believ remain track deliv
strong mid-singl digit revenu growth double-digit adj ep growth
align orchestr
analyst day interest hear manag believ
next major era develop era orchestr accord manag
orchestr connect peopl break silo way
work connect variou platform creat one streamlin intellig workflow one
ecosystem tie togeth clinic data real world evid cloud platform
orchestr interact trial design start-up contact close
orchestr platform built around iqvia variou applic reli
three primari capabl lexi ada apollo ada use artifici intellig ai
orchestr tradit manual task predict intellig apollo standard interfac
help streamlin workflow lexi data reportedli help promot uninterrupt flow
data result streamlin workflow cloud platform support continuum
clinic trial design close
figur iqvia orchestr
orchestr ad benefit creat larg address market across
four domain clinic real world complianc commerci manag explain
see larg market opportun rel iqv annual revenu find
market opportun larg compel
figur orchestr help drive impress
 learn almost none iqv trial current orchestr
much area growth compani futur direct manag comment
suggest current use modul trial goal
trial orchestr clinic trial mani modul havent introduc yet
mean opportun orchestr clinic trial remain attract upsid growth
reimagin clinic trial trial
interest hear analyst day iqv quest transform clinic
develop goal complet up-end tradit clinic trial model offer
abil complet virtual trial accord manag individu live two
hour given clinic research facil make recruit particip much
difficult decentr clinic trial creat virtual trial imagin
could streamlin process speed time take start trial reduc time take
recruit patient make entir trial process easier patient custom
figur reimagin clinic trial
everyth would done virtual reli tool like telemedicin imagin
could improv data qualiti consist improv trial process begin make
virtual trial realiti partner salesforc accord manag
virtual trial base referr hub studi hub referr hub focus
expedit recruit studi hub orchestr aspect trial
figur reimagin clinic trial
virtual trial sound like excit opportun great way disrupt improv
tradit clinic trial model told virtual trial
current underway technolog remain young sound like still earli
stage howev manag sound optimist virtual trial model could catch
enabl multi-countri studi easier patient custom
consolid payer shift valu drive shift novel
among variou pressur impact life scienc industri highlight
analyst day payer consolid rise specialti pharmaceut product
increasingli pressur tradit commerci agreement drug product follow
vertic integr cvs-aet ci-esrx three payer control pbm
market base data drug channel institut meanwhil costli specialti medic
continu increas number increas percent total drug spend repres
drug spend conjunct larger shift valu explain
see increas pressur creat new payment model tie dollar outcom
figur strong payer growth specialti pressur tradit agreement
accord compani desir tie payment outcom condit durat
therapi present opportun compani de-identifi patient
record one million data feed collect healthcar record annual accord
compani vast reach access longitudin data uniqu posit compani
help facilit shift novel commerci agreement tie payment outcom
condit
exampl explain track data around complet treatment plan
sequenc use cumul dose indic use durat therapi metric upon
base new payment agreement view sound like excit opportun
believ shift valu continu increas preval import high-
cost specialti pharmaceut product like necessit use new payment mechan
tie spend result
model updat increas pt
remain posit view invest technolog past
year pay form increas win rate divis rapid top-
line growth technolog servic increas long-term guidanc believ
iqv data asset technolog solut unmatch say
variou data capabl enabl select doctor trial site believ
softwar use highli robust advanc believ data technolog
asset lead higher win rate improv trial time effect site select
higher satisfact level across board increas revenu
earn estim slightli account rapid top-lin growth increas pt
given stock strong perform past year iqvia trade histor
averag believ well deserv iqvia price-to-earnings ratio slightli ahead
averag slightli ahead comp group averag
similarli ev/ebitda standpoint ahead comp group
averag next month expect share trade pt
averag ep estim
ev/ebitda believ deserv premium rel histori given abil
continu drive growth competit industri captur valu end market
continu look innov
risk valuat
iqvia like becom heavili invest certain clinic trial success trial
key drive futur revenu high profil trial produc neg result
possibl compani suffer sunk cost elimin futur revenu
opportun relat commerci futur opportun compani
work
possibl mani pharmaceut biotechnolog compani iqvia
custom earli stage compani run start-up fund compani
unabl continu rais money fuel product clinic trial pre-approv
process iqvia posit market may suffer addit macro standpoint
signific market downturn could addit neg effect iqvia gener
inabl rais money market place relat individu compani product
possibl regul us countri updat approv process
requir new drug way drug commerci iqvia fail
react quickli chang may risk lose current potenti custom
competitor chang regul may increas difficulti process
may put addit strain smaller life scienc compani iqvia work creat
increas financi burden increas overal risk compani chang
regul clinic trial space like requir signific updat exist
applic potenti develop new applic futur regard
commerci chang regul may limit use vast amount data
iqvia util would limit potenti compani offer increas valu
custom
trial may risk compani experi shortag drug test
could result potenti loss custom expect revenu iqvia furthermor
navig drug shortag import issu compani util iqvia commerci
solut drug shortag result headwind custom possibl iqvia
potenti revenu futur relationship affect custom suffer
iqvia compet highli competit market compet
also healthcar technolog compani specif focus develop roll
applic help life scienc compani carri clinic trial addit
may use solut develop compani increas use case
solut well potenti life scienc compani use solut trial
road iqvia work develop solut
orchestr custom engag delay disrupt perform either clinic
commerci side busi may result custom attrit
iqvia unabl enrol suffici number patient custom trial
revenu stream would like risk unabl identifi enough patient like
custom would termin contract iqvia would suffer delay futur
iqvia establish one lead healthcar databas world store
data non-identifi breach may neg implic compani term
privaci well compet cloud base compani captur similar data
iqvia may leader use data reput implic would like benefit
custom furthermor data privaci law chang possibl use
data may neg impact base certain inform would like
headwind futur perform
consolid life scienc industri may limit amount servic offer
iqvia abl provid consolid may drive increas penetr individu
compani product servic offer scale basi like
product util two compani would gener revenu one compani
combin util two base initi cost structur
increas level consolid industri may threat potenti growth
busi like compani measur captur increas util
iqvia gener indemnifi insur patient harm possibl
reput would suffer drug trial caus harm patient financi harm also
possibl loss revenu life scienc compani work well
potenti lawsuit may involv
iqvia custom depend produc accur relev inform time
must ensur full complianc strict chang regul failur provid
inform compli regul includ audit trail data encrypt secur access
specif industri regul may limit compani abil perform advers affect
stock price
on-going litig iqvia alleg unlaw use
intellectu properti improv promot market data offer veeva also file
countersuit alleg anticompetit behavior seek punit damag litig cost
litig potenti becom high profil process given two compani involv
major player life scienc industri end rule iqvia favor may
face financi damag well limit potenti grow futur increas
incom statement fye decemb
million
revenu
research develop solut
revenu
revenu
revenu excl
revenu
sell gener administr expens
revenu
depreci amort
revenu
revenu
loss extinguish debt
loss extinguish debt
restructur relat charg
incom non-control interest
minor interest effect non-gaap adjust
incom statement fye decemb
million
non-gaap gaap net incom reconcili
provis incom tax
depreci amort
incom loss unconsolid affili
incom non-control interest
loss extinguish debt
restructur relat charg
gaap net incom attribut inc
net incom attribut non control interest
equiti earn unconsolid affili
incom equiti earn unconsol affili
provis incom tax
incom loss unconsolid affili
incom non-control interest
loss extinguish debt
restructur relat charg
incom non-control interest
minor interest effect non-gaap adjust
gaap net incom attribut inc
add back equiti earn unconsolid affili
incom statement fye decemb
million
revenu
segment revenu
revenu mix
sell gener administr expens
segment revenu
research develop solut
revenu
segment revenu
revenu mix
sell gener administr expens
segment revenu
contract sale medic solut
revenu
segment revenu
revenu mix
sell gener administr expens
segment revenu
incom statement fye decemb
million
revenu geographi
gener corpor unalloc
gener corpor unalloc cost
total revenu
depreci amort
total revenu
total revenu
total revenu
total incom oper
